About Genmab AS
Genmab AS (NASDAQ:GMAB) is a biotech firm focusing on creating transformative antibody therapies for cancer treatment. The company is traded on the NASDAQ under the ticker symbol GMAB and on the Copenhagen Stock Exchange as (CSE:GEN). Genmab's operations span the discovery and development of novel monoclonal antibodies, a type of protein designed to interact with specific targets in the body. Its projects include proprietary product candidates and partnerships with other pharmaceutical companies to leverage its technology platforms, DuoBody, HexaBody, DuoHexaBody, and HexElect. Genmab's objectives center on using its innovative antibody technology to address unmet medical needs in oncology, aiming to improve the lives of cancer patients worldwide. The company's commitment to innovation and patient care drives its ongoing research, development, and commercialization efforts in the field of cancer therapeutics.
Snapshot
Operations
Produtos e/ou serviços de Genmab AS
- Daratumumab (Darzalex), a groundbreaking antibody for treating multiple myeloma by targeting CD38-expressing cancer cells.
- Teprotumumab (Tepezza), a first-in-class treatment for Thyroid Eye Disease (TED), operating as an insulin-like growth factor I receptor inhibitor.
- Ofatumumab (Arzerra), developed for chronic lymphocytic leukemia, acts by targeting the CD20 molecule on B cells.
- Tisotumab vedotin, an innovative antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer, targeting tissue factor.
- DuoBody-CD3xCD20, a bispecific antibody platform designed to target CD3 on T cells and CD20 on B cells, aimed at treating B-cell malignancies.
- HexaBody-DR5/DR5, aimed at engaging the death receptor 5 (DR5) to induce apoptosis in cancer cells, represents a novel approach in targeted cancer therapy.
equipe executiva do Genmab AS
- Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO
- Mr. Anthony Pagano CPAExecutive VP & CFO
- Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer
- Mr. Christopher CozicExecutive VP & Chief People Officer
- Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer
- Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director
- Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer
- Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines
- Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director
- Mr. Takahiro HamataniSenior Director of Finance Japan & Non-Independent Director